{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:57:20Z","timestamp":1790697440229,"version":"4.1.0"},"reference-count":51,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI19C1328"],"award-info":[{"award-number":["HI19C1328"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Venous thromboembolism (VTE) is a leading cause of mortality in cancer patients, and a substantial number of patients are being treated with oral anticoagulants. We aim to assess the comparative effectiveness of direct oral anticoagulants (DOACs) compared to warfarin for VTE treatment in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, we included 2,367 cancer patients who are new users of oral anticoagulants (OACs) for VTE treatment from 2009 to 2021 in NHS Scotland. Patients were grouped by OAC type, DOACs or warfarin. To adjust for confounding, inverse probability treatment weighting was applied. Outcomes included mortality, VTE recurrence, and major bleeding. We calculated Hazard Ratio (HR) using Cox regression and sub\u2010distribution HR (sHR) using a competing risk framework (Fine and Gray method) for VTE recurrence and major bleeding. Subgroup analyses were conducted for individual DOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients on DOACs had lower risks of VTE recurrence (sHR 0.73 95% CI 0.59\u20130.90) and major bleeding (sHR 0.68, 95% CI 0.53\u20130.88) compared to patients on warfarin. Patients on rivaroxaban (HR 1.21, 95% CI 1.04\u20131.39) and edoxaban (HR 1.59, 95% CI 1.15\u20132.22) had a significantly higher risk of mortality, while a comparable risk of mortality was observed (HR 0.91, 95% CI 0.76\u20131.08) for patients on apixaban compared to patients on warfarin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides insight into the effectiveness of DOACs compared to warfarin for VTE in cancer patients. Patients on DOACs had lower risks of VTE recurrence and major bleeding. We suggest healthcare professionals consider the potential benefits of individual DOACs when making treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71209","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:59:18Z","timestamp":1757411958000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-7011","authenticated-orcid":false,"given":"Hye\u2010In","family":"Jung","sequence":"first","affiliation":[{"name":"School of Pharmacy Sungkyunkwan University  Suwon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Geue","sequence":"additional","affiliation":[{"name":"Health Economics and Health Technology Assessment (HEHTA), University of Glasgow  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ciminata","sequence":"additional","affiliation":[{"name":"Health Economics and Health Technology Assessment (HEHTA), University of Glasgow  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-7754","authenticated-orcid":false,"given":"Eui\u2010Kyung","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Pharmacy Sungkyunkwan University  Suwon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.10.015"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2007.02374.x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.11.1245"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.01.028"},{"key":"e_1_2_11_6_1","volume-title":"Cancer\u2010Associated Venous Thromboenbolic Disease","author":"NCCN","year":"2022"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.08.003"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0119-2018"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007338"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.12.001"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14662"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.09.037"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0046"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.014"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003442"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00160-7"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02073.x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12002"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.07.013"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004012"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1718728"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25283"},{"key":"e_1_2_11_25_1","unstructured":"\u201cApixaban (Eliquis) \u201dUpdated 12 December 2011 https:\/\/www.scottishmedicines.org.uk\/medicines\u2010advice\/apixaban\u2010eliquis\u2010fullsubmission\u201074111\/."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw060"},{"key":"e_1_2_11_27_1","unstructured":"Groups HR \u201cISB 0070: Healthcare Resource Groups (HRGs) \u201dhttp:\/\/www.hscic.gov.uk\/hrg."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.10.035"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14071"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2298"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002268"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-11-200312020-00007"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262293"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016\u20100414"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007901"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4973"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019\u20100482"},{"issue":"4","key":"e_1_2_11_39_1","first-page":"188","article-title":"Charlson Comorbidity Index: ICD\u20109 Update and ICD\u201010 Translation","volume":"12","author":"Glasheen W. P.","year":"2019","journal-title":"American Health & Drug Benefits"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH15\u201008\u20100686"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/096228029900800102"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895\u20104356(00)00321\u20108"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5705"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10742-013-0109-2"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006650.pub5"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07653-9"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2003.12.020"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(14)70018\u20103"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1046864"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25494"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:31:17Z","timestamp":1761129077000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":51,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cam4.71209"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71209","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71209"}}